At the end of June, results from a Phase 3 clinical trial were published showing that a cocktail of metabolic activators including Nicotinamide Riboside “NR” (FAQs) (Reviews) significantly reduced recovery time in mild to moderate COVID-19 patients. Previously, in response to Phase 2 results, Dr. Charles Brenner (who discovered NR as an NAD precursor vitamin) commented on Twitter: “I expect NR was driver of the beneficial effects in ppl“. And now that the full Phase 3 study results have finally been published, Dr Brenner said the following on a mid-July podcast (video embedded below):

At the 48:16 minute mark of the video podcast below:

“Just in the last month, there was a study that came out that was peer-reviewed from Turkey and Sweden in which Nicotinamide Riiboside (NR) high dose — so, like, two grams a day — was included in a cocktail of essentially over-the-counter molecules like N-acetyl-L-cysteine (NAC), L-serine, and L-carnitine I believe.

And I don’t fully understand why the other three were included (excluding NR).

But the trial was for COVID recovery.

And we published a paper last year on how coronavirus infection in cell systems attacks the NAD system.

We understand how it works.

And we made predictions and had some pretty convincing preclinical data that a higher NAD status would boost the innate immune system.

And we’re very encouraged to see that this dietary supplement mixture that included high dose NR greatly accelerated time to recovery of mild to moderate COVID patients in placebo-controlled studies.

So we think that there’s some exciting things coming out.

But we want to see things done safely”.

RELATED:

FOLLOW us on Twitter @RaisingNAD